Intestinal mucosal inflammatory pathways

Intestinal mucosal inflammatory pathways represent a complex network of immune and signaling processes that maintain gut homeostasis or drive chronic inflammation when dysregulated (Sánchez de Medina et al., 2014). These pathways involve the coordinated action of pro-inflammatory cytokines such as TNF-alpha, IL-12, and IL-23, as well as leukocyte trafficking mediated by integrins like alpha-4 beta-7 (NIH, 2024). In diseases such as Crohn's disease and ulcerative colitis, an inappropriate immune response to the microbiota leads to persistent mucosal damage and barrier dysfunction (Wikipedia, 2024). Therapeutic strategies target specific components within these pathways, including the use of monoclonal antibodies to neutralize cytokines (e.g., infliximab) or block cell adhesion (e.g., vedolizumab) (Otte et al., 2023). Additionally, small molecules like Janus kinase (JAK) inhibitors and sphingosine-1-phosphate (S1P) receptor modulators are used to interrupt intracellular signaling and lymphocyte egress (Bentham Science, 2003; NIH, 2024). Achieving mucosal healing through these targeted interventions is a primary clinical goal to ensure long-term remission and reduce complications (WJG, 2023).

Other names

Gut mucosal inflammatory cascadesIntestinal immune signaling pathwaysMucosal inflammatory responseIBD inflammatory pathways

Inhibition of pro-inflammatory cytokines (TNF-alpha, IL-12, IL-23), antagonism of integrin-mediated leukocyte trafficking, inhibition of Janus kinases (JAK1, JAK2, JAK3, TYK2), and modulation of sphingosine-1-phosphate (S1P) receptors.